Overview
Tagrisso 80 mg Tablets contain Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI). It is primarily used for treating non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M-positive and exon 19 deletions or exon 21 (L858R) substitutions. Tagrisso is indicated both as first-line therapy and for patients whose cancer has progressed following prior EGFR-TKI treatment.





